GH Secretagogues Special-Populations Summary

What Is the GH Secretagogues Drug Class?

GH secretagogues are a structurally diverse group of agents that share one functional outcome: they increase the amplitude or frequency of endogenous GH pulses from anterior pituitary somatotrophs. They do not deliver exogenous GH. Because the pituitary retains its own feedback sensitivity, GHS therapy preserves the physiological pulsatility of GH release, which distinguishes it mechanistically from recombinant human GH (rhGH) replacement.

Two Receptor Families, One Downstream Effect

The class divides cleanly into two receptor-based subgroups.

GHRH receptor agonists mimic growth hormone-releasing hormone. Sermorelin (the first FDA-approved GHRH analog, approved 1997) and tesamorelin (a stabilized GHRH[1-44] analog) act here. CJC-1295 is a longer-acting GHRH analog that, in its DAC (Drug Affinity Complex) formulation, binds albumin to extend half-life to approximately 8 days compared with minutes for native GHRH [1].

Ghrelin receptor (GHS-R1a) agonists include the growth hormone-releasing peptides (GHRPs): GHRP-6, GHRP-2, hexarelin, and ipamorelin. MK-677 (ibutamoren) is an orally active non-peptide GHS-R1a agonist studied in multiple Phase II and III trials [2]. Ipamorelin is considered the class prototype for clinical use because it produces selective GH release without the cortisol, prolactin, or ACTH co-secretion seen with GHRP-6 at equivalent doses [3].

Why Pulsatility Matters Clinically

Continuous GH elevation, as occurs with supraphysiologic rhGH dosing, down-regulates GHS-R1a and IGF-1 receptors. GHS agents, by contrast, amplify natural nocturnal GH bursts. A 2001 NEJM study of elderly subjects (N=65) demonstrated that GHRH analog infusion restored GH pulse amplitude toward youthful norms without fully suppressing the feedback axis [4]. This preservation of feedback is the pharmacological argument for preferring GHS over exogenous GH in most outpatient settings.

Ipamorelin: Class Prototype Pharmacology

Ipamorelin is a pentapeptide GHRP with a selectivity profile that makes it the default first-choice agent in most compounded peptide protocols.

Receptor Selectivity and Side-Effect Profile

At doses of 200-300 mcg subcutaneous (SC), ipamorelin produces a GH pulse without meaningfully elevating cortisol or prolactin [3]. GHRP-6, by contrast, produces a significant cortisol spike at equimolar doses, which limits its use in patients with anxiety disorders, insomnia, or adrenal insufficiency. Hexarelin causes dose-dependent cardiac receptor desensitization with repeated use. Ipamorelin avoids both liabilities.

Standard Dosing and Timing

Ipamorelin is typically dosed at 200-300 mcg SC, 1-3 times daily. The most pharmacologically rational timing is 30-60 minutes before sleep, when the dominant physiological GH pulse occurs [5]. Co-administration with CJC-1295 without DAC (the "modified GRF 1-29" form) at the same dose and timing is the most common clinical protocol, combining GHRH-R and GHS-R1a stimulation for additive pulse amplitude.

Peak serum GH occurs approximately 15-30 minutes post-injection. IGF-1 levels, the preferred long-term monitoring biomarker, typically rise measurably within 4-8 weeks of consistent use.

Tesamorelin: The Only FDA-Approved GHS for Adults

Tesamorelin (Egrifta, then Egrifta SV) received FDA approval in 2010 for reducing excess abdominal fat in HIV-infected adults with lipodystrophy [6]. It is the only GHS with full FDA approval for adult use, giving it a unique evidentiary standing within the class.

The LIPO-010 trial (N=412) showed tesamorelin 2 mg SC daily reduced visceral adipose tissue (VAT) by a mean of 18.1% versus 0.5% with placebo at 26 weeks (P<0.0001) [7]. Trunk fat by DXA was reduced by 6.8% compared with a 0.1% increase in the placebo group.

For practitioners writing compounded GHRH analog prescriptions off-label, tesamorelin's trial data supply the most rigorous dose-response and safety benchmarks in the class. The FDA label specifies contraindication in disruption of the hypothalamic-pituitary axis (pituitary tumor, hypopituitarism after irradiation), pregnancy, and known hypersensitivity.

MK-677 (Ibutamoren): The Oral Option

MK-677 is the only orally bioavailable GHS in clinical use. Its mechanism, selective GHS-R1a agonism, produces sustained 24-hour GH and IGF-1 elevation rather than discrete pulses.

Trial Evidence

The MK-677-012 trial (N=292 healthy elderly subjects, mean age 72) showed that MK-677 25 mg daily for 12 months increased IGF-1 by approximately 40% and improved thigh muscle volume by 1.7 kg lean mass versus placebo, but did not improve functional outcomes on the six-minute walk test [2]. A separate 2-year trial in elderly hip-fracture patients (N=123) showed no reduction in falls or fractures at 25 mg daily [8].

Practical Caveats

The non-pulsatile GH profile from MK-677 produces more fluid retention (edema in 22% of subjects in MK-677-012) and insulin resistance than equivalent-amplitude pulsatile protocols. Fasting glucose should be checked every 8 weeks in all MK-677 users. In patients with prediabetes (A1C 5.7-6.4%), MK-677 requires careful monitoring and may need to be deferred.

Special Populations: Older Adults (Age 60+)

Somatopause, the age-related decline in GH secretion, begins in the fourth decade and accelerates after 60. By age 70, mean 24-hour GH secretion is approximately 50% below peak adult values, with corresponding IGF-1 decline [4]. This is the population for which GHS therapy has the strongest physiological rationale.

Dose Adjustments

Older adults are more sensitive to GH-axis stimulation. Start ipamorelin at 100-150 mcg SC once nightly rather than 200-300 mcg. Titrate to an IGF-1 target in the lower half of the age-adjusted reference range (typically 100-200 ng/mL for patients aged 60-75) rather than pushing toward youthful reference ranges.

MK-677 in older adults requires particular attention to fluid balance and glucose. The 12-month MK-677-012 trial reported worsening fasting glucose in 27% of subjects [2]. For older patients with pre-existing metabolic syndrome, pulsatile SC protocols (ipamorelin plus CJC-1295 without DAC) offer better glucose tolerance than continuous MK-677 stimulation.

Monitoring Schedule

Check IGF-1 at baseline, 8 weeks, and every 12 weeks thereafter. Check fasting glucose and HbA1c at baseline and 12 weeks. In patients with osteoporosis, a DEXA scan at 12 months gives objective data on lean mass and bone density response.

Special Populations: Women

Women present a distinct GH-axis physiology. Estrogen amplifies GH pulse amplitude, so premenopausal women generally have higher basal IGF-1 than age-matched men [9]. Postmenopausal women lose this estrogen-driven amplification and experience somatopause that overlaps with declining estrogen.

Premenopausal Women

In premenopausal women, GHS therapy is rarely indicated for body composition alone, given normal GH secretion. The more common clinical scenario is recovery from overtraining, surgery, or traumatic injury. Ipamorelin at 100-200 mcg SC nightly for 8-12 weeks is a reasonable trial. Monitor IGF-1 closely. Women's IGF-1 reference ranges are age-stratified; a 35-year-old woman with an IGF-1 of 280 ng/mL on GHS therapy is above the mean and should have the dose reduced.

Postmenopausal Women

In postmenopausal women, especially those already on menopausal hormone therapy (MHT), the interaction between estrogen and GH secretion matters. Oral estrogen reduces hepatic IGF-1 production relative to transdermal estrogen at equivalent systemic doses [10]. A postmenopausal woman on oral estradiol may show a blunted IGF-1 response to GHS despite adequate GH pulse stimulation. Switching to transdermal estrogen, if clinically appropriate, before interpreting IGF-1 response to GHS can prevent unnecessary dose escalation.

Pregnancy and Lactation

GHS agents are contraindicated in pregnancy. Tesamorelin's FDA label carries a pregnancy category X classification under the legacy FDA system [6]. Animal data for GHRP class agents show fetal weight suppression at high doses. No human lactation data exist for any compounded GHS. Women who may become pregnant should use reliable contraception throughout GHS therapy.

Special Populations: Competitive and Masters Athletes

The World Anti-Doping Agency (WADA) prohibits all GHS class agents under Section S2 of the Prohibited List, classifying them alongside peptide hormones and growth factors [11]. This applies to all competition levels subject to WADA jurisdiction.

The Masters Athlete Scenario

A common clinical presentation: a 50-year-old recreational masters-category athlete requests ipamorelin for recovery. The patient competes in events not subject to WADA testing. In this case, GHS use is a clinical decision, not a doping violation. However, prescribers should document the patient's competitive status and confirm they are not subject to anti-doping testing in writing before initiating treatment.

For athletes, dose timing relative to training matters. GH's anabolic effects on connective tissue peak 6-8 hours after GH pulse stimulation [5]. Injecting ipamorelin 30 minutes before sleep aligns the subsequent GH-driven IGF-1 rise with early morning, when structural protein synthesis is highest.

The Three-Question Pre-Prescription Screen for Athletes

Before prescribing GHS to any athlete, answer these three questions:

1. Is this patient subject to WADA, USADA, or sport-specific anti-doping testing? If yes, do not prescribe.
2. Does the patient have an IGF-1 below the lower quartile for age and sex? If yes, there is a stronger physiological justification.
3. Does the patient have any active musculoskeletal injury requiring healing? Recovery of tendon and cartilage tissue may be the primary indication in this group.

Special Populations: Patients With Metabolic Disease

Obesity and Insulin Resistance

Obesity blunts GH secretion through two mechanisms: elevated free fatty acids suppress hypothalamic GHRH, and elevated insulin suppresses GHS-R1a sensitivity [12]. As a result, obese patients may require higher GHS doses to achieve the same IGF-1 response as lean counterparts, and they paradoxically have the most to gain from restoring GH pulsatility.

In patients with a BMI above 35, ipamorelin at 300 mcg SC nightly is a reasonable starting dose, with IGF-1 target in the mid-normal range for age. Weight loss of 10-15% of body weight from concurrent GLP-1 receptor agonist therapy (e.g., semaglutide 2.4 mg weekly per the STEP-1 trial, N=1,961, which produced 14.9% mean weight loss at 68 weeks [13]) can independently restore GH pulse amplitude, sometimes obviating the need for GHS entirely.

Type 2 Diabetes

GH is a counter-regulatory hormone. Elevated GH reduces peripheral insulin sensitivity, which is why acromegaly almost universally causes secondary diabetes. GHS therapy at low-to-moderate doses produces a more modest and transient IGF-1 elevation than acromegaly, but insulin resistance remains a real risk.

In patients with Type 2 diabetes, GHS therapy is not absolutely contraindicated but requires a documented clinical justification beyond body composition. Check HbA1c and fasting glucose before starting. If HbA1c exceeds 8.0%, optimize glycemic control before initiating GHS. During therapy, check fasting glucose every 4-6 weeks for the first 6 months.

The 2021 American Diabetes Association Standards of Care note that GH excess directly impairs beta-cell function and increases hepatic glucose output [14]. Prescribers should consider this when titrating GHS doses in any diabetic patient.

Active Malignancy

GH and IGF-1 are mitogenic. IGF-1 signaling through the IGF-1 receptor (IGF-1R) promotes cell proliferation and inhibits apoptosis in multiple tumor types [15]. Active malignancy is an absolute contraindication to all GHS agents. Patients in cancer remission present a harder clinical decision. The standard practice in endocrinology is a minimum 5-year remission period before considering rhGH replacement in GH-deficient adults, and the same conservative threshold applies to GHS therapy [16].

Special Populations: Pediatric Patients

Compounded GHS agents have no established safety or efficacy data in pediatric populations. The only FDA-approved growth hormone secretagogue in pediatrics is sermorelin acetate for injection, and its approval was withdrawn from the market in 2008 (though the compound remains available through compounding pharmacies in the US). Prescribing compounded GHS to patients under 18 requires exceptional documentation of need, absence of approved alternatives, and informed consent from both patient and guardian.

Open epiphyses represent the critical safety concern. Supraphysiologic GH stimulation before growth plate closure could accelerate bone age and reduce adult height. Any pediatric GHS use should be co-managed with a pediatric endocrinologist and monitored with bone age X-rays every 6 months.

Monitoring Protocol Across All Populations

All GHS prescriptions should include a structured monitoring protocol. The table below outlines minimum intervals.

| Parameter | Baseline | 8 Weeks | 12 Weeks | Every 6 Months | |---|---|---|---|---| | IGF-1 | Yes | Yes | Yes | Yes | | Fasting glucose | Yes | Yes (MK-677) | Yes | Yes | | HbA1c | Yes | No | Yes | Yes | | CBC, CMP | Yes | No | Yes | Yes | | Blood pressure | Yes | Yes | Yes | Yes | | DEXA (body comp) | Optional | No | No | Yes | | Symptom review (edema, paresthesia, arthralgia) | Yes | Yes | Yes | Yes |

IGF-1 values consistently above the upper limit of the age-adjusted reference range are the primary dose-reduction signal. The Endocrine Society's 2011 Clinical Practice Guideline on Adult GH Deficiency states: "The goal of GH therapy is to normalize serum IGF-1 to a level within the age- and sex-adjusted reference range" [16]. The same target applies to GHS-mediated IGF-1 elevation.

Regulatory and Compounding Considerations

The practical reality of GHS prescribing in the US is that most agents (ipamorelin, CJC-1295, GHRP-6, GHRP-2, sermorelin) are obtained through 503A or 503B compounding pharmacies. The FDA issued guidance in 2023 placing several peptides, including ipamorelin and CJC-1295, on the Category 2 list for consideration as "difficult to compound" or lacking adequate clinical evidence for compounding, creating regulatory uncertainty for prescribers [17].

Prescribers should verify their compounding pharmacy's accreditation (PCAB accreditation from the Pharmacy Compounding Accreditation Board is the relevant credential), confirm USP <797> sterility compliance for all injectable preparations, and document medical necessity in the patient record.